🔗 Share this article

While America undertakes sweeping revisions to its vaccine recommendations, a particular individual has surfaced somewhat surprisingly: Høeg, a Danish American physician and public health researcher who rose to prominence by questioning coronavirus shots during the global health crisis and has focused upon potential fatalities following COVID-19 immunization in her short time at the FDA.

Proposed Changes to Pediatric Vaccine Schedule

Agency leaders were set to announce major changes to the childhood vaccine schedule recently, synchronizing the US with Denmark’s vaccine program, according to reports – a major change that would put the US out of step with a large portion of the world with little proof for improved outcomes. The planned update has been postponed until the coming year.

Instead of Vinay Prasad, Tracy Beth Høeg is listed to present at the meeting. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to head the center this calendar year.

A New Direction at the Regulatory Body

Høeg's temporary position might represent a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has repeatedly called for halting some childhood vaccine recommendations in the US in order to be more similar to the Danish model, a country with universal health coverage and a citizenry roughly the size of Wisconsin’s.

To date public appearances, she has continued to focus on immunizations – traditionally the purview of Prasad, director of the FDA’s vaccine center – instead of medication approval.

Doubts Over Expertise

Dr. Høeg has no obvious background in drug development, approval processes or administrative roles, which has been standard for former directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the agency head and the vaccine center since spring.

“She appears not to have the requisite experience” for overseeing the pharmaceutical oversight division, said Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in managing a major agency. She has no expertise in industry regulation.”

Previous heads of CBER would “understand regulatory frameworks and the underlying principles of pharmaceutical innovation”, noted Janet Woodcock. “Clearly, she has not acquired the type of experience that former directors who led the center have had.”

This division has an vast workload at the FDA, she emphasized.

“The public just zeroes in on the new drug program, but the off-patent medication office approves thousands of off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and so forth, and each of these need to be supervised,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Furthermore, a significant administrative element to the job, which supervises over 5,000 personnel. “It is a huge management job, if you perform it correctly,” the former official concluded.

Official Statement and Disputed Initiatives

Regarding concerns about Høeg’s qualifications and whether this appointment signifies increased cooperation among regulatory chiefs on vaccines, a spokesperson said that the “inquiries are based on incorrect presumptions”.

“Her experience aligns with the duties of her position,” the spokesperson said, citing the time Høeg spent advising the FDA commissioner on “drug safety and oversight research, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg takes over the agency head's controversial expedited review system, a contentious rapid medication authorization process that apparently concerned her former heads. “By what process are these therapies being chosen for this fast-track system? Who takes the choices?” Howard asked. “There’s a lot of confidentiality occurring at the FDA right now.”

Overall, he stated, “the FDA appears to be shifting towards more relaxed oversight of most medications, with the exception of shots.”

Public Past Work on Vaccines

Regarding immunizations, Høeg has a more established, if concerning, past, some experts have noted. She authored a study using unverified crowd-sourced reports to estimate the rate of myocarditis after COVID-19 vaccination. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to indicate COVID-19 vaccinations are riskier than they are.

Part of her “desired changes” for the new administration included revising rules for new vaccines and halting “unnecessary” immunizations, she remarked after the election on a podcast. At the FDA, Dr. Høeg has allegedly suggested barring adolescent males from obtaining Covid vaccinations.

“She is an all-around true believer who begins with her conclusions and tailors the evidence to fit the science in a extremely misleading, fraudulent fashion,” Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with other dissenters, {like|